Orforglipron (Foundayo, LY3502970)

Orforglipron is a small-molecule GLP-1 receptor agonist designed for once-daily oral administration. Despite its non-peptide chemistry, it activates the same GLP-1 receptor as semaglutide and tirzepatide, producing the canonical effects of slowed gastric emptying, glucose-dependent insulin secretion, and central appetite suppression.

Orforglipron was originally discovered by Chugai Pharmaceutical and is being developed by Eli Lilly. It is part of a small but consequential class of orally bioavailable, non-peptide GLP-1 receptor agonists, molecules engineered to activate the GLP-1 receptor through a different binding mode than native peptide agonists, allowing oral administration without the complex absorption strategies needed for peptides.

The Phase 3 program (ACHIEVE in T2D, ATTAIN in obesity) supported FDA approval for weight management on April 1, 2026, making once-daily oral GLP-1 therapy a mainstream option for the first time.

Orforglipron binds to the GLP-1 receptor at a different site from peptide agonists, providing similar receptor activation through a small-molecule scaffold. The downstream signaling and physiologic effects are the same as the peptide GLP-1 class, appetite suppression, glycemic control, slowed gastric emptying, but the chemistry enables oral bioavailability.^[1]

Orforglipron has a half-life of approximately 29–49 hours, supporting once-daily oral dosing. Critically, and unlike Rybelsus (oral semaglutide), which requires fasting administration with strict water timing, orforglipron has demonstrated absorption that is largely independent of food and water intake, simplifying real-world adherence.

The peer-reviewed literature on Orforglipron is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity, supported claims, claims that look promising but need more data, and claims that outrun the science.

Phase 3 trials use once-daily oral dosing without strict food / fasting requirements. Following FDA approval on April 1, 2026, orforglipron is commercially available in the US as Foundayo by prescription.

Orforglipron is now the first once-daily oral GLP-1 small molecule approved for weight management, cleared by the FDA on April 1, 2026 as Foundayo. Because it sidesteps both peptide-synthesis manufacturing and the food-timing rules that constrain Rybelsus, it changes access dynamics and real-world adherence in a market that weekly injectables have dominated. The diabetes indication is still working through the ACHIEVE program.

FDA approval (April 2026)

The FDA approved orforglipron on April 1, 2026 under the brand name Foundayo, for adults with obesity, or overweight with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. It is the first oral GLP-1 receptor agonist approved for weight management that carries no food or water timing restrictions — a practical contrast with oral semaglutide (Rybelsus), which requires dosing on an empty stomach with limited water and a wait before eating.

Because orforglipron is a small molecule rather than a peptide, it avoids peptide-synthesis manufacturing constraints, which is the main reason its approval is treated as a supply-and-access event as much as a clinical one. Approval does not by itself resolve questions of long-term durability, cardiovascular outcomes, or how it compares head-to-head with injectable incretins; those remain active research questions. See our orforglipron outlook article for the trial background.